Annals of Emergency Medicine
Volume 45, Issue 3 , Pages 299-301 , March 2005

Improving Quality of Asthma Care After Emergency Department Discharge: Evidence Before Action

  • Brian H. Rowe, MD, MSc

      Affiliations

    • Corresponding Author InformationAddress for correspondence: Brian Rowe, MD, MSc, Department of Emergency Medicine, 1G1.43 WMC, 8440-112 Street, Edmonton, Alberta, Canada T6R 1A5; 780-407-6707, fax 780-407-3982
    • ,
  • Sumit R. Majumdar, MD, MPH

References 

  1. Mannino DM, Homa DM, Pertowski CA, et al. Surveillance for asthma—United States, 1960-1995. CDC Surveillance Summaries, April 24, 1998. MMWR. 1998;47:1–28
  2. Weiss KB, Sullivan SD, Lyttle CS. Trends in the cost of illness for asthma in the United States, 1985-1994. J Allergy Clin Immunol. 2000;106:493–499
  3. Krahn MD, Berka C, Langlois P, et al. Direct and indirect costs of asthma in Canada. Can Med Assoc J. 1996;154:821–831
  4. Rowe BH, Spooner CH, Ducharme FM, et al. Corticosteroids for preventing relapses following acute exacerbations of asthma. (Cochrane Review) In: The Cochrane Library, Issue 3. Chichester, United Kingdom: John Wiley & Sons, Ltd; 2004;
  5. Rowe BH, Bota GW, Fabris L, et al. Inhaled budesonide in addition to oral corticosteroids to prevent relapse following discharge from the emergency department: a randomized controlled trial. JAMA. 1999;281:2119–2126
  6. Emerman CL, Woodruff PG, Cydulka RK, et al. Prospective multicenter study of relapse following treatment for acute asthma among adults presenting to the emergency department. Chest. 1999;115:919–927
  7. Singer AJ, Camargo CA, Lampell M, et al. A call for expanding the role of the emergency physician in the care of patients with asthma. Ann Emerg Med. 2005;45:295–298
  8. Edmonds ML, Camargo CA, Brenner B, et al. Inhaled steroids in acute asthma following emergency department discharge. (Cochrane Review) In: The Cochrane Library, Issue 3. Chichester, United Kingdom: John Wiley & Sons, Ltd; 2004;
  9. Bierman AS, Bell CM. Penny-wise, pound foolish: the costs of cost-related medication restriction. Med Care. 2004;42:623–625
  10. Kelso TM, Self TH, Rumbak MJ, et al. Educational and long-term therapeutic intervention in the ED: effect on outcomes in adult indigent minority asthmatics. Am J Emerg Med. 1995;13:632–637
  11. Levy ML, Robb M, Allen J, et al. A randomized controlled evaluation of specialist nurse education following accident and emergency department attendance for acute asthma. Resp Med. 2000;94:900–908
  12. Gibson PM, Powell H, Coughlan J, et al. Limited (information only) patient education programs for adults with asthma. (Cochrane Review) In: The Cochrane Library, Issue 4. Chichester, United Kingdom: John Wiley & Sons, Ltd; 2004;
  13. Gibson PM, Coughlan J, Wilson AJ, et al. Self-management education and regular practitioner review for adults with asthma. (Cochrane Review) In: The Cochrane Library, Issue 3. Chichester, United Kingdom: John Wiley & Sons, Ltd; 2004;
  14. Harrison TW, Oborne J, Newton S, et al. Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial. Lancet. 2004;363:271–275
  15. Baren JM, Roberts J, Clark S, et al. Randomized controlled trial of two simple ED interventions to improve the rate of primary care follow-up for patients with acute asthma: 6-month follow-up results. [abstract] Acad Emerg Med. 2002;9:211
  16. Sin DD, Bell NR, Man SF. Effects of increased primary care access on process of care and health outcomes among patients with asthma who frequent emergency departments. Am J Med. 2004;11:479–483
  17. Majumdar SR, Rowe BH, Folk D, et al. Increasing the detection and treatment of osteoporosis in patients who present to an emergency department with a wrist fracture. Ann Intern Med. 2004;141:366–373
  18. Overhage JM, Dexter PR, Perkins SM, et al. A randomized, controlled trial of clinical information shared from another institution. Ann Emerg Med. 2004;39:14–23

 Funding and support: Dr. Rowe is supported as a Canada Research Chair in Emergency Airway Diseases through the Canadian Institutes of Health Research. Dr. Majumdar is supported as a Population Health Investigator through the Alberta Heritage Foundation for Medical Research and a New Investigator from the Canadian Institutes of Health Research. Dr. Rowe has received funding for research and/or speaking from the following companies: Abbott (Chicago, IL), AstraZeneca (Mississauga, Ontario, Canada), Aventis (Montreal, Quebec, Canada), Boehringer-Ingelheim Corporation (Ridgefield, CT), and GlaxoSmithKline (Mississauga, Ontario, Canada); however, he is neither a paid employee nor a consultant for any of these companies and has no financial interests in these companies. Dr. Majumdar has no conflicts of interest, financial or otherwise, to disclose.Reprints not available from the authors.

PII: S0196-0644(04)01742-1

doi: 10.1016/j.annemergmed.2004.11.026

Annals of Emergency Medicine
Volume 45, Issue 3 , Pages 299-301 , March 2005

Article Tools